Insight Molecular DiagnosticsIMDX +1.66%49 Gross Margin % is 46.88% as of Mar. 2026, which is 40% above its 10-year median of 33.41. GuruFocus rates IMDX with a GF Score™ of 49/100 and a GF Value™ of $1.26 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 195 Medical Diagnostics & Research companies, Insight Molecular Diagnostics ranks better than 50.26% on this metric.
IMDX's Gross Margin % is ranked better than 50.26% of 195
companies
in the Medical Diagnostics & Research industry
Industry Median: 50.97
vs IMDX: 51.31
Insight Molecular Diagnostics had a gross margin of 46.88% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Insight Molecular Diagnostics had a gross margin of 46.88% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Insight Molecular Diagnostics Gross Margin % Related Terms
Insight Molecular Diagnostics Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IMDX vs BDSX, XGN, FONR: Gross Margin % Comparison
For the Diagnostics & Research subindustry, Insight Molecular Diagnostics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Insight Molecular Diagnostics Gross Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Insight Molecular Diagnostics's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Insight Molecular Diagnostics's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Insight Molecular Diagnostics (IMDX) has a Gross Margin % of 46.88% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Insight Molecular Diagnostics and its competitors. This is 40% above median its historical median of 33.41. According to the industry distribution chart, Insight Molecular Diagnostics ranks #97 out of 195 companies in the Medical Diagnostics & Research industry, placing it in the top 49.7%.
Is Insight Molecular Diagnostics' Gross Margin % too high?
Insight Molecular Diagnostics' current Gross Margin % of 46.88% is 40% above median its 10-year median of 33.41. The Medical Diagnostics & Research industry median Gross Margin % is 50.97. Insight Molecular Diagnostics' value of 46.88% is 8% below this industry median. Based on the distribution chart, Insight Molecular Diagnostics ranks #97 out of 195 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Insight Molecular Diagnostics has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Insight Molecular Diagnostics' Gross Margin % compare to BDSX and XGN?
According to the Medical Diagnostics & Research industry distribution chart, Insight Molecular Diagnostics ranks #97 out of 195 companies for Gross Margin %. This puts Insight Molecular Diagnostics in the upper half of its industry. The industry median Gross Margin % is 50.97. Insight Molecular Diagnostics' value of 46.88% is 8% below this benchmark. While the company's 10-year median is 33.41 vs. the industry median of 50.97, Insight Molecular Diagnostics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Diagnostics & Research company?
The median Gross Margin % among Medical Diagnostics & Research companies is 50.97, based on 195 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Insight Molecular Diagnostics's current Gross Margin % of 46.88% is 8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Insight Molecular Diagnostics and its competitors. For the Medical Diagnostics & Research industry, the median Gross Margin % is 50.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Insight Molecular Diagnostics's current Gross Margin % is 46.88%, which is 40% above median its own 10-year median of 33.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Insight Molecular Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Insight Molecular Diagnostics (IMDX) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.26, compared to a current price of $5.51 — trading 337.3% above its estimated fair value. The current Gross Margin % is 46.88%, which is 40% above median its 10-year median of 33.41 and 8% below the Medical Diagnostics & Research industry median of 50.97. Insight Molecular Diagnostics' overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Insight Molecular Diagnostics (IMDX), the current Gross Margin % is 46.88% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Insight Molecular Diagnostics (IMDX) Overvalued in 2026?
Based on GuruFocus' analysis, Insight Molecular Diagnostics stock appears to be overvalued.
The current stock price of $5.51 is trading 337.3% above its estimated GF Value™ of $1.26.
GuruFocus considers Insight Molecular Diagnostics to be Significantly Overvalued.
Key valuation signals for IMDX:
Gross Margin %: 46.88% (40% above median its 10-year median of 33.41)
GF Value™: $1.26 vs. price of $5.51 (337.3% above fair value)
Industry Position: 8% below the Medical Diagnostics & Research median (#97 of 195)
No single metric tells the full story. See the IMDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Insight Molecular Diagnostics Business Description
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.
49GF Score
Get the complete analysis for IMDX
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IMDX has been successfully added to your 
